Viewing nowEmpagliflozin 25 mg Tablet
Empagliflozin 25mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

MFDS item code 202105613 · Approved 2021.07.29 · Insurance code 671808000
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medicine is used in conjunction with diet and exercise to help control blood sugar levels in adults with type 2 diabetes. It can also be used as monotherapy and in combination with other medications. It is particularly effective when blood sugar control is inadequate. For patients with type 2 diabetes who have cardiovascular disease, caution regarding the occurrence of cardiovascular events is advised, and consultation with a specialist is recommended. This medicine improves blood sugar control and aids in diabetes management.
The recommended dose of this medicine for monotherapy and as add-on combination therapy with other glucose-lowering agents, including insulin, is 10 mg once daily. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, section 3. Adverse Reactions). This medicine may be taken regardless of food. Swallow the tablet whole. If a dose is missed, take it as soon as remembered. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary for patients with mild renal impairment. Do not initiate treatment with this medicine in patients with an estimated glomerular filtration rate (eGFR) below 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well but have a persistent estimated glomerular filtration rate below 60ml/min/1.73m2 [or CrCl < 60 ml/min], adjust or maintain the dose of this medicine at 10 mg once daily. Discontinue this medicine if the estimated glomerular filtration rate decreases to below 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those undergoing dialysis, as efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as they have not been studied. •Older adults No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years and older. Initiation of this medicine is not recommended in patients aged 85 years and older because clinical experience is limited (see Precautions for Use, section 4. General Precautions)
This medicine should not be used in patients who have allergic reactions to the active ingredient or any components. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis. Use of this medicine is not recommended in patients with severely impaired renal function, end-stage renal disease, or those undergoing dialysis. Since this medicine contains lactose, it should not be used in patients with lactose intolerance, galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. Caution is required when administering to patients with slightly impaired renal function, and dosage adjustment or discontinuation is necessary if the glomerular filtration rate falls below a certain level. Use in patients with mild or moderate heart failure should be approached with caution, while its use is not recommended for severe heart failure patients. When this medicine is used in conjunction with insulin or insulin secretagogues, there may be a risk of hypoglycemia, necessitating dosage adjustments. Caution should be taken for the possibility of hypoglycemia when used alongside sulfonylureas or insulin, and symptoms should be monitored. Side effects such as genital infections, urinary tract infections, increased urination, etc., can occur, especially genital infections are more common in women. Due to fluid volume decrease, dehydration or low blood pressure may occur, therefore elderly patients or those taking antihypertensive medications should be cautious. Rarely, serious metabolic acidosis known as ketoacidosis may occur, necessitating immediate treatment upon symptoms. Cases of liver damage have been reported, so careful observation is necessary if there are suspected liver function abnormalities. It is important to regularly monitor renal function while on this medication. Use during pregnancy is not recommended, and the medication should be discontinued upon confirmation of pregnancy. For nursing women, it is advisable to discontinue breastfeeding while taking this medication. Safety and efficacy in pediatric patients under 18 years of age have not been established. While no special toxicity has been reported for overdose, appropriate treatment is required based on clinical condition. Caution is necessary while driving or operating machinery due to the risk of hypoglycemia. Severe adverse effects such as limb amputation have been reported, hence careful foot care is essential. Rare serious infections such as perineal necrosis may occur, so healthcare providers should be notified immediately if related symptoms occur. This medicine may interact with other medications, so it is crucial to inform healthcare providers of all medications being taken.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly closed container to prevent air or moisture from entering. The storage temperature should be maintained between 1 degree and 30 degrees Celsius at room temperature. This helps to preserve the effectiveness of the medication for a longer period.
Pale yellow oval film-coated tablets
30 tablets/PTP [(10 tablets/PTPX3)], 10 tablets/PTP [(10 tablets/PTPX1)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Daewoong Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.